Carna Biosciences Inc. (4572)

Overview

Carna Biosciences, Inc. is a trailblazing clinical-stage biopharmaceutical company based in Kobe, Japan, dedicated to the discovery and development of innovative drug therapies aimed at addressing unmet medical needs. Incorporated in 2003, Carna Biosciences stands at the forefront of research in Japan, leveraging its expertise to advance treatments for various diseases. The company is characterized by its strategic collaborations with industry giants such as Johnson & Johnson, Sierra Oncology, Sumitomo Dainippon Pharma, Gilead Sciences, and BioNova Pharmaceuticals, underscoring its commitment to healthcare innovation and therapeutic development.

Products and Services

Carna Biosciences, Inc. offers a comprehensive portfolio of products and services designed to meet the demands of the biopharmaceutical industry, including:

• Kinase Proteins: High-quality enzymes that are pivotal for signal transduction processes and cellular regulation, valuable in the development of targeted therapies.
• Substrates: Essential components for kinase assays, these substrates enable researchers to investigate kinase activity and function, facilitating the identification of potential drug candidates.
• Kinase Protein Assay Kits: Ready-to-use kits for the analysis and measurement of kinase activity, providing essential tools for drug discovery and research laboratories.
• Stable Cell Lines: Engineered cell lines that express specific proteins or reporters, critical for understanding disease mechanisms and for drug screening applications.
• Biotinylated Kinases: Kinases labeled with biotin, allowing for easy capture and detection in various assay formats, supporting the study of kinase interactions and functions.
• Profiling Services: Comprehensive kinase screening services to determine the specificity and efficacy of potential kinase inhibitors, aiding in the early stages of drug development.
• NanoBRET TE Intracellular Kinase Cell-Based Assay: A cutting-edge technology for measuring kinase activity in live cells, facilitating the real-time assessment of drug effects on kinase function.
• Protein Detection and Interaction Services: Advanced techniques for detecting proteins and analyzing their interactions, crucial for drug target identification and validation.
• Live-Cell Kinase Assay Services: Services designed to evaluate kinase inhibitors in a cellular context, offering insights into drug efficacy and cellular responses.
• Tyrosine Kinase Cell-Based Assay Services: Specialized assays for the study of tyrosine kinases, which play a critical role in the signaling pathways that regulate cell division and growth.

Beyond its extensive range of services, Carna Biosciences is also actively involved in the development of pioneering drugs for the treatment of cancer and other significant health challenges. Its pipeline includes AS-0141, a CDC7 kinase inhibitor in preclinical trials for cancer treatment; AS-0871, a small molecule drug in Phase 1 clinical trials aimed at inflammatory and immune disorders; and AS-1763, a non-covalent inhibitor targeting chronic lymphocytic leukemia and other B cell malignancies, currently in preclinical trials. These endeavors underscore Carna Biosciences’ relentless pursuit of transformative healthcare solutions.